Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced the addition of
Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s
board of directors.

“We are extremely pleased to add these two experienced executives to
Sage’s board of directors. As Sage continues to advance its programs in
development, adding an executive with Liz’s expertise in scaling
businesses and launching products globally will be invaluable,” said
Jeff Jonas, M.D., chief executive officer of Sage. “We are just as
excited to announce that George Golumbeski will be joining our board.
Sage has opened the door to a new way of thinking about treating brain
disorders, and we believe George’s decades of experience growing
companies and advancing innovation through corporate strategy and
development will help us achieve our mission of improving lives of
people living with CNS disorders.”

Liz Barrett is the president and chief executive officer of UroGen, a
clinical-stage biopharmaceutical company focused on non-surgical
uro-oncology treatments. She previously served as chief executive
officer of Novartis Oncology. In that role, she oversaw more than 10,000
associates in 85 countries and was a member of the Novartis executive
committee. Prior to Novartis, she was global president, oncology at
Pfizer Inc., where she held a series of leadership positions, including
president, Europe, global innovative pharma, president, North America,
and president, U.S. oncology business unit. Prior to Pfizer, Ms. Barrett
was vice president and general manager of the oncology business unit at
Cephalon Inc., where she launched the company into oncology. She has
also held senior roles at Johnson & Johnson, working across their
oncology, diagnostics, consumer products, and hospital and orthopedic
markets sectors.

“Sage’s approach to developing new treatment paths for serious brain
disorders is analogous to the work I have led to transform cancer care,”
said Ms. Barrett. “I am honored to join a team where bold bets are made,
and conventional wisdom is challenged to find important solutions for
patients and their healthcare providers.”

George Golumbeski is the president of GRAIL, a health-care company
focused on the early detection of cancer. Dr. Golumbeski previously
served as executive vice president of Celgene, leading corporate
development. During his nine years at Celgene, he fostered new models
for inter-company collaboration, and saw Celgene named “Partner of
Choice” in the biotechnology industry. Prior to Celgene, Dr. Golumbeski
was vice president of business development, licensing, and strategy at
Novartis. He also held leadership positions at Elan Pharmaceuticals and
Schwarz Pharma, where he focused on neurology and neuropsychiatry
therapeutics.

“I am truly pleased to join the team at Sage. Personally, I am deeply
aligned with Sage’s commitment to non-incremental innovation and deep
science. It is also terribly exciting to return to work on medicines for
disorders of the central nervous system, an area of utmost medical need,
and the therapeutic area where I began my career,” said Dr. Golumbeski.
“I look forward to working with the leadership of Sage as it progresses
through many strategic and corporate development crossroads.”

About Sage Therapeutics
Sage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing novel
medicines to transform the lives of patients with life-altering CNS
disorders. Sage's lead product candidate, ZULRESSO™ (brexanolone)
injection, has completed Phase 3 clinical development for postpartum
depression and a New Drug Application is currently under review with the
U.S. Food and Drug Administration. Sage is developing a portfolio of
novel product candidates targeting critical CNS receptor systems,
including SAGE-217, which is in Phase 3 development in major depressive
disorder and postpartum depression. For more information, please visit www.sagerx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005079/en/